Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy

Haematologica. 2008 Jan;93(1):e9-10. doi: 10.3324/haematol.11782.
No abstract available

Publication types

  • Case Reports
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Benzoates / adverse effects*
  • Benzoates / therapeutic use
  • Cataract / chemically induced*
  • Child
  • Child, Preschool
  • Deferasirox
  • Humans
  • Iron Chelating Agents / adverse effects*
  • Iron Chelating Agents / therapeutic use
  • Italy
  • Time Factors
  • Triazoles / adverse effects*
  • Triazoles / therapeutic use
  • beta-Thalassemia / drug therapy*

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Deferasirox